Article
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer.
Current medical research and opinion - 1 Oct 2020
Yoh Kiyotaka, Atagi Shinji, Reck Martin, Garon Edward B, Ponce Aix Santiago, Moro-Sibilot Denis, Winfree Katherine B, Frimodt-Moller Bente, Zimmermann Annamaria, Visseren-Grul Carla, Nakagawa Kazuhiko
Abstract excerpt
OBJECTIVE: In the phase 3 RELAY trial, ramucirumab/erlotinib demonstrated superior progression-free survival (PFS) over placebo/erlotinib in patients with EGFR-mutated metastatic NSCLC (median PFS 19.4 versus 12.4 months; HR = 0.59, 95% CI = 0.46-0.76; p < .0001). Safety was consistent with established profiles for ramucirumab and erlotinib in NSCLC. Here, we present patient-reported outcomes. METHODS: Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.